Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Aktis Oncology has raised $175.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
Aktis Oncology's investors include RA Capital Management, Eli Lilly, Janus Henderson Investors, Novartis, Vida Ventures.
Aktis Oncology is headquartered in Boston, United States.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Aktis Oncology is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aktis Oncology — Funding & Investors." VCBacked, September 30, 2024, https://www.vcbacked.co/company/aktis-oncology. Accessed October 28, 2026.
VCBacked. (2024). Aktis Oncology — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/aktis-oncology
{{cite web |title=Aktis Oncology — Funding & Investors |url=https://www.vcbacked.co/company/aktis-oncology |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated